Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang and Ambrx Start Phase I Trial of HER2 Cancer Drug

publication date: Mar 22, 2016
Zhejiang Medicine and Ambrx, a San Diego biotech that develops antibody drug conjugates, have started a Phase I trial of ARX788, an antibody targeting HER2 cancer. The trial will be conducted at several sites in Australia and New Zealand in patients with metastatic HER2-positive breast cancer. Zhejiang, which owns China rights to ARX788, has also filed with the CFDA to begin trials of the drug in China. In 2013, Zhejiang obtained rights to develop the drug in China from Ambrx. More details....

Stock Symbol: (SHA: 600216)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital